1014 related articles for article (PubMed ID: 19117685)
1. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
[TBL] [Abstract][Full Text] [Related]
2. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Ganten TM; Haas TL; Sykora J; Stahl H; Sprick MR; Fas SC; Krueger A; Weigand MA; Grosse-Wilde A; Stremmel W; Krammer PH; Walczak H
Cell Death Differ; 2004 Jul; 11 Suppl 1():S86-96. PubMed ID: 15105837
[TBL] [Abstract][Full Text] [Related]
3. [Progress on targeting TRAIL's receptor as antitumor strategy].
Chen SZ
Yao Xue Xue Bao; 2009 Dec; 44(12):1336-42. PubMed ID: 21351465
[TBL] [Abstract][Full Text] [Related]
4. Control of apoptosis signaling by Apo2 ligand.
Marsters SA; Pitti RA; Sheridan JP; Ashkenazi A
Recent Prog Horm Res; 1999; 54():225-34. PubMed ID: 10548878
[TBL] [Abstract][Full Text] [Related]
5. The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis.
Colucci S; Brunetti G; Cantatore FP; Oranger A; Mori G; Pignataro P; Tamma R; Grassi FR; Zallone A; Grano M
Apoptosis; 2007 Sep; 12(9):1623-32. PubMed ID: 17558561
[TBL] [Abstract][Full Text] [Related]
6. Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Kim K; Fisher MJ; Xu SQ; el-Deiry WS
Clin Cancer Res; 2000 Feb; 6(2):335-46. PubMed ID: 10690508
[TBL] [Abstract][Full Text] [Related]
7. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL.
Riccioni R; Pasquini L; Mariani G; Saulle E; Rossini A; Diverio D; Pelosi E; Vitale A; Chierichini A; Cedrone M; Foà R; Lo Coco F; Peschle C; Testa U
Haematologica; 2005 May; 90(5):612-24. PubMed ID: 15921376
[TBL] [Abstract][Full Text] [Related]
8. TRAIL death receptors and cancer therapeutics.
Huang Y; Sheikh MS
Toxicol Appl Pharmacol; 2007 Nov; 224(3):284-9. PubMed ID: 17240413
[TBL] [Abstract][Full Text] [Related]
9. Targeting TRAIL towards the clinic.
Mahalingam D; Oldenhuis CN; Szegezdi E; Giles FJ; de Vries EG; de Jong S; Nawrocki ST
Curr Drug Targets; 2011 Dec; 12(14):2079-90. PubMed ID: 21777191
[TBL] [Abstract][Full Text] [Related]
10. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
Gómez-Benito M; Martinez-Lorenzo MJ; Anel A; Marzo I; Naval J
Exp Cell Res; 2007 Jul; 313(11):2378-88. PubMed ID: 17462628
[TBL] [Abstract][Full Text] [Related]
11. TRAIL receptor signaling and therapeutics.
Abdulghani J; El-Deiry WS
Expert Opin Ther Targets; 2010 Oct; 14(10):1091-108. PubMed ID: 20819019
[TBL] [Abstract][Full Text] [Related]
12. Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.
Secchiero P; Zauli G
Curr Opin Hematol; 2008 Jan; 15(1):42-8. PubMed ID: 18043245
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.
Liu XS; Zhu Y; Han WN; Li YN; Chen LH; Jia W; Song CJ; Liu F; Yang K; Li Q; Jin BQ
Hybrid Hybridomics; 2003 Apr; 22(2):121-5. PubMed ID: 12831538
[TBL] [Abstract][Full Text] [Related]
15. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
Rowinsky EK
J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
[TBL] [Abstract][Full Text] [Related]
16. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
Mérino D; Lalaoui N; Morizot A; Schneider P; Solary E; Micheau O
Mol Cell Biol; 2006 Oct; 26(19):7046-55. PubMed ID: 16980609
[TBL] [Abstract][Full Text] [Related]
17. Modulation of death receptor pathways in oncology.
de Vries EG; Timmer T; Mulder NH; van Geelen CM; van der Graaf WT; Spierings DC; de Hooge MN; Gietema JA; de Jong S
Drugs Today (Barc); 2003; 39 Suppl C():95-109. PubMed ID: 14988748
[TBL] [Abstract][Full Text] [Related]
18. TRAIL as a target in anti-cancer therapy.
Wu GS
Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma.
Arts HJ; de Jong S; Hollema H; ten Hoor K; van der Zee AG; de Vries EG
Gynecol Oncol; 2004 Mar; 92(3):794-800. PubMed ID: 14984943
[TBL] [Abstract][Full Text] [Related]
20. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
